Pre-clinical studies have suggested that PARPi resistance in BRCA1 mutant cancers could emerge via loss of DNA end resection inhibitors (e.g. 53BP1, REV7, Shieldin) and the restoration of DNA resection (see earlier). The gene discussed is BRCA1; the disease is cancer.